Advances in technology for detecting measurable residual disease (MRD) are also raising questions regarding the role of MRD in managing multiple myeloma.
Lauren Dembeck, PhDContributing Writer https://www.cancertherapyadvisor.com
Lauren Dembeck is a freelance science and medical writer and a contributing author for the Haymarket Medical Network. She holds a BS in biology and a BA in foreign languages from West Virginia University and a PhD in genetics from North Carolina State University. Prior to freelance writing, Lauren was a postdoctoral researcher at the Okinawa Institute of Science and Technology in Japan, where she studied developmental neurobiology. You can find more of her writing at https://laurendembeck.com/